A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study
4
Issued Date
2026-04-01
Resource Type
eISSN
20597029
Scopus ID
2-s2.0-105032419049
Journal Title
ESMO Open
Volume
11
Issue
4
Rights Holder(s)
SCOPUS
Bibliographic Citation
ESMO Open Vol.11 No.4 (2026)
Suggested Citation
Ryu S.Y., Nam B.H., Kim M.H., Jang W.I., Sitathanee C., Linh T.D., Lee K.H., Lee W.M., Kim E.T., Kang S.B., Kim J.H., Park J.Y., Lee K.B., Cho C.H., Lou H., Kim Y.H., Kim Y.T., Lee Y.H., Wu X., Kim J.W., Park S.I., Jeon S., Thinh D.H., Kry S.F., Gaffney D., Small W., Wilailak S. A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study. ESMO Open Vol.11 No.4 (2026). doi:10.1016/j.esmoop.2026.106102 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115739
Title
A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study
Author's Affiliation
Fudan University
The University of Texas MD Anderson Cancer Center
University of Utah School of Medicine
Hanyang University
Seoul National University College of Medicine
Asan Medical Center
Gachon University
Soonchunhyang University
The Catholic University of Korea Seoul St. Mary's Hospital
Stritch School of Medicine
Severance Hospital
Kyungpook National University School of Medicine
Keimyung University
Ewha Womans University School of Medicine
Ramathibodi Hospital
Gangnam Severance Hospital
Korea Institute of Radiological and Medical Sciences
Kosin University
Ho Chi Minh City Oncology Hospital
Dongnam Institute of Radiological & Medical Sciences
Hosan Women's Hospital
Data Management Center
Zheijiang Cancer Center
The University of Texas MD Anderson Cancer Center
University of Utah School of Medicine
Hanyang University
Seoul National University College of Medicine
Asan Medical Center
Gachon University
Soonchunhyang University
The Catholic University of Korea Seoul St. Mary's Hospital
Stritch School of Medicine
Severance Hospital
Kyungpook National University School of Medicine
Keimyung University
Ewha Womans University School of Medicine
Ramathibodi Hospital
Gangnam Severance Hospital
Korea Institute of Radiological and Medical Sciences
Kosin University
Ho Chi Minh City Oncology Hospital
Dongnam Institute of Radiological & Medical Sciences
Hosan Women's Hospital
Data Management Center
Zheijiang Cancer Center
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: The standard treatment for locally advanced cervical cancer is cisplatin-based chemoradiotherapy; however, the optimal dose and dosing schedule of cisplatin remain debated. The aim of this study was to compare the clinical outcomes of weekly cisplatin at 40 mg/m<sup>2</sup> versus those of tri-weekly cisplatin at 75 mg/m<sup>2</sup> during radiation in patients with locally advanced cervical cancer. Patients and methods: In this prospective, randomized clinical trial, we enrolled 314 patients with stage IIB-IVA cervical cancer, randomly assigning them in a 1: 1 ratio into two arms. The weekly arm received a weekly dose of 40 mg/m<sup>2</sup> cisplatin for six cycles, whereas the tri-weekly arm received a tri-weekly dose of 75 mg/m<sup>2</sup> cisplatin for three cycles, both concurrently with radiotherapy. The primary endpoints included 3-year recurrence-free survival according to a superiority design, with P < 0.05 indicative of statistical significance. Overall survival, toxicity profiles, and quality of life (QOL) were also analyzed. Results: Chemotherapy delay was more frequent in the weekly arm than in the tri-weekly arm (P = 0.008). However, the 3-year recurrence-free survival rate between the two arms did not significantly differ (78.7% in the weekly arm, 84.1% in the tri-weekly arm; hazard ratio 0.71, 95% confidence interval 0.39-1.32, P = 0.28). The pattern of recurrence did not differ significantly between the two arms. Grade 3 and 4 hematological toxicities occurred less frequently in the tri-weekly arm (P < 0.001). Furthermore, the tri-weekly arm had better QOL scores across several domains compared with the weekly arm. Conclusion: In this study, tri-weekly cisplatin-based chemoradiotherapy was not statistically superior to a weekly schedule in terms of survival outcomes for patients with locally advanced cervical cancer. However, the tri-weekly regimen exhibited a more favorable toxicity profile and improved QOL compared with the weekly regimen. These results suggest tri-weekly cisplatin administration as a feasible alternative for chemoradiotherapy in cervical cancer.